Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640068 | 1.00 | HDAC1 (0.58) | HDAC1HDAC2HDAC3RAB9AHDAC4 | |
| SCHEMBL2638719 | 0.92 | HDAC1 (0.49) | HDAC1HDAC2HDAC3HDAC4MEF2D | |
| SCHEMBL2638720 | 0.92 | HDAC1 (0.49) | HDAC1HDAC2HDAC3HDAC4MEF2D | |
| SCHEMBL2638771 | 0.91 | HDAC1 (0.48) | HDAC1HDAC2HDAC3HDAC4MEF2D | |
| SCHEMBL2638769 | 0.91 | HDAC1 (0.48) | HDAC1HDAC2HDAC3HDAC4MEF2D | |
| SCHEMBL1965849 | 0.87 | HDAC1 (0.62) | HDAC1HDAC2HDAC3RAB9AHDAC4 | |
| SCHEMBL1972507 | 0.87 | HDAC1 (0.62) | HDAC1HDAC2HDAC3RAB9AHDAC4 | |
| SCHEMBL10039315 | 0.85 | HDAC1 (0.76) | HDAC1HDAC2HDAC3RAB9AHDAC4 | |
| SCHEMBL2639046 | 0.84 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC4MEF2D | |
| SCHEMBL2639042 | 0.84 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC4MEF2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | claimed |
| JP-2011526936-A | — | — | 2011-10-20 | — | — | JP | claimed |
| WO-2010031708-A2 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | claimed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | claimed |
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2010031708-A2 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | HDAC1 730/4885HDAC2 1799/4885HDAC3 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.